Verrica Pharmaceuticals (VRCA) investor relations material

Business overview and recent progress

• Focused on dermatology with two late-stage assets addressing unmet needs in molluscum contagiosum and common warts.

• CEO rejoined about a year ago to reframe commercial strategy and pipeline execution.

• Achieved sequential quarter-over-quarter growth in dispensed units for Wycanth, the commercial asset for molluscum.

• Wycanth has permanent J code, NC designation, and Orange Book listing.

• Partnership with Torii Pharmaceutical in Japan includes milestone payments and global Phase III program for common warts.

Product pipeline and clinical data

• Wycanth is FDA-approved for molluscum contagiosum in patients aged two and up, with strong clinical data showing rapid and significant lesion clearance.

• Adverse events are mostly mild to moderate local skin reactions; no serious events reported.

• Phase II program for common warts showed 51% complete resolution and robust persistence; global Phase III to start by year-end.

• VP315 for basal cell carcinoma completed Phase II, showing 51% complete histological clearance and 86% tumor size reduction.

• No treatment-related adverse events in VP315 Phase II; dual mechanism of action supports further development.

Commercial strategy and market access

• Expanded access for Wycanth to pediatricians, dermatologists, and primary care, with dual buy-and-bill and specialty pharmacy options.

• Robust Medicaid and commercial insurance coverage, with $25 copay assistance for up to two applicators.

• Endorsement by AAP Red Book in 2024 highlights Wycanth's active ingredient as a preferred treatment.

• Incremental revenue opportunity for clinicians via procedure codes; 225 million lives covered under insurance programs.

• Specialty pharmacy delivery optimized for national and local access.